Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study

被引:965
作者
Albers, Gregory W.
Thijs, Vincent N.
Wechsle, Lawrence
Kemp, Stephanie
Schlaug, Gottfried
Skalabrin, Elaine
Bammer, Roland
Kakuda, Wataru
Lansberg, Maarten G.
Shuaib, Ashfaq
Coplin, William
Hamilton, Scott
Moseley, Michael
Marks, Michael P.
机构
[1] Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA
[2] Stanford Univ, Med Ctr, Stroke Ctr, Palo Alto, CA 94304 USA
[3] Stanford Univ, Med Ctr, Dept Radiol, Palo Alto, CA 94304 USA
[4] Univ Hosp Leuven, Dept Neurol, Louvain, Belgium
[5] Univ Pittsburgh, UPMC Stroke Inst, Pittsburgh, PA USA
[6] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA
[7] Beth Israel Deaconess Med Ctr, Div Cerebrovasc Disorders, Boston, MA 02215 USA
[8] Harvard Univ, Sch Med, Boston, MA USA
[9] Univ Utah, Dept Neurol, Salt Lake City, UT USA
[10] Univ Alberta, Dept Med, Div Neurol, Edmonton, AB, Canada
关键词
D O I
10.1002/ana.20976
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine whether prespecified baseline magnetic resonance imaging (MRI) profiles can identify stroke patients who have a robust clinical response after early reperfusion when treated 3 to 6 hours after symptom onset. Methods: We conducted a prospective, multicenter study of 74 consecutive stroke patients admitted to academic stroke centers in North America and Europe. An MRI scan was obtained immediately before and 3 to 6 hours after treatment with intravenous tissue plasminogen activator 3 to 6 hours after symptom onset. Baseline MRI profiles were used to categorize patients into subgroups, and clinical responses were compared based on whether early reperfusion was achieved. Results: Early reperfusion was associated with significantly increased odds of achieving a favorable clinical response in patients with a perfusion/diffusion mismatch (odds ratio, 5.4; p = 0.039) and an even more favorable response in patients with the Target Mismatch profile (odds ratio, 8.7; p = 0.011). Patients with the No Mismatch profile did not appear to benefit from early reperfusion. Early reperfusion was associated with fatal intracranial hemorrhage in patients with the Malignant profile. Interpretation: For stroke patients treated 3 to 6 hours after onset, baseline MRI findings can identify subgroups that are likely to benefit from reperfusion therapies and can potentially identify subgroups that are unlikely to benefit or may be harmed.
引用
收藏
页码:508 / 517
页数:10
相关论文
共 35 条
[2]   Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke [J].
Alsop, DC ;
Makovetskaya, E ;
Kumar, S ;
Selim, M ;
Schlaug, G .
STROKE, 2005, 36 (04) :746-750
[4]   Generalized efficacy of t-PA for acute stroke - Subgroup analysis of the NINDS t-PA stroke trial [J].
Brott, T ;
Broderick, J ;
Kothari, R ;
ODonoghue, M ;
Barsan, W ;
Tomsick, T ;
Spilker, J ;
Miller, R ;
Sauerbeck, L ;
Farrell, J ;
Kelly, J ;
Perkins, T ;
Miller, R ;
McDonald, T ;
Rorick, M ;
Hickey, C ;
Armitage, J ;
Perry, C ;
Thalinger, K ;
Rhude, R ;
Schill, J ;
Becker, PS ;
Heath, RS ;
Adams, D ;
Reed, R ;
Klei, M ;
Hughes, A ;
Anthony, J ;
Baudendistel, D ;
Zadicoff, C ;
Rymer, M ;
Bettinger, I ;
Laubinger, P ;
Schmerler, M ;
Meiros, G ;
Lyden, P ;
Dunford, J ;
Zivin, J ;
Rapp, K ;
Babcock, T ;
Daum, P ;
Persona, D ;
Brody, M ;
Jackson, C ;
Lewis, S ;
Liss, J ;
Mahdavi, Z ;
Rothrock, J ;
Tom, T ;
Zweifler, R .
STROKE, 1997, 28 (11) :2119-2125
[5]   Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke [J].
Brown, DL ;
Johnston, KC ;
Wagner, DP ;
Haley, EC .
STROKE, 2004, 35 (01) :147-150
[6]   Refining the perfusion-diffusion mismatch hypothesis [J].
Butcher, KS ;
Parsons, M ;
MacGregor, L ;
Barber, PA ;
Chalk, J ;
Bladin, C ;
Levi, C ;
Kimber, T ;
Schultz, D ;
Fink, J ;
Tress, B ;
Donnan, G ;
Davis, S .
STROKE, 2005, 36 (06) :1153-1159
[7]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[8]   The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g) - Results of a double-blind, placebo-controlled, multicenter study [J].
Clark, WM ;
Albers, GW ;
Madden, KP ;
Hamilton, S .
STROKE, 2000, 31 (04) :811-816
[9]   Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage -: A multicenter study on the validity of stroke imaging [J].
Fiebach, JB ;
Schellinger, PD ;
Gass, A ;
Kucinski, T ;
Siebler, M ;
Villringer, A ;
Ölkers, P ;
Hirsch, JG ;
Heiland, S ;
Wilde, P ;
Jansen, O ;
Röther, J ;
Hacke, W ;
Sartor, K .
STROKE, 2004, 35 (02) :502-506
[10]  
FISHER M, 1995, JAMA-J AM MED ASSOC, V274, P908